Predicting Immunotherapy Success for Lung Cancer
Intratumoral microbiota and immune predictors of response to immunotherapy in lung cancer
This project looks at bacteria inside tumors and immune cells to help predict which lung cancer patients will respond best to immunotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11139591 on NIH RePORTER |
What this research studies
Immunotherapy is a powerful treatment for advanced lung cancer, but it doesn't work for everyone. We want to find better ways to predict who will benefit most from these treatments and understand why some patients don't respond. Our team is looking closely at the types of bacteria found within lung tumors and how immune cells behave in the tumor environment. By combining this information, we hope to create a model that can accurately tell us which patients are most likely to respond to immunotherapy. This could help doctors choose the best treatment path for each individual.
Who could benefit from this research
Good fit: This research focuses on patients with advanced Non-Small Cell Lung Cancer who have received or are considering immune checkpoint inhibitor therapy.
Not a fit: Patients who do not have lung cancer or are not candidates for immunotherapy would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more personalized treatment plans for lung cancer patients, ensuring they receive the most effective immunotherapy.
How similar studies have performed: While the role of the tumor microenvironment and microbiota in immunotherapy response is an active area of investigation, this specific integrative predictive model is a novel approach.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Liu, Yanhong — Baylor College of Medicine
- Study coordinator: Liu, Yanhong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.